Kakabadse, Dimitri, Chen, Dawei, Fishman, Sigal, Weinstein-Marom, Hadas, Davies, Joanne, Wen, Li, Gross, Gideon and Wong, F. Susan  ORCID: https://orcid.org/0000-0002-2812-8845
      2024.
      
      Regulatory CD4 + T cells redirected against pathogenic CD8 + T cells protect NOD mice from development of autoimmune diabetes.
      Frontiers in Immunology
      15
      
      
      , 1463971.
      10.3389/fimmu.2024.1463971
    
  
    
    
       
    
  
  
         | 
      
| 
            
PDF (Data sheet)
 - Supplemental Material
 Download (190kB)  | 
        |
| 
            
PDF
 - Published Version
 Download (5MB)  | 
        
Abstract
Introduction: In this study, we report a novel therapeutic approach redirecting antigen-specific CD4+ T cells recognizing a hybrid insulin peptide (BDC2.5 T cell receptor (TCR) transgenic CD4+ T cells) to attract and suppress islet-specific CD8+ T cells T cells in the non-obese diabetic (NOD) mouse model, and prevent the development of autoimmune diabetes. Methods: Purified BDC2.5 CD4+ T cells were induced to differentiate into regulatory T cells (Tregs). The Tregs were then electroporated with mRNA encoding chimeric human β2 microglobulin (hβ2m) covalently linked to insulin B chain amino acids 15-23 (designated INS-eTreg) or islet-specific glucose-6-phosphatase related protein (IGRP) peptide 206-214 (designated IGRP-eTreg). Immunoregulatory functions of these engineered regulatory T cells (eTregs) were tested by in vitro assays and in vivo co-transfer experiments with β-cell-antigen-specific CD8+ T cells in NOD.Scid mice or by adoptive transfer into young, pre-diabetic NOD mice. Results: These eTregs were phenotyped by flow cytometry, and shown to have high expression of FoxP3, as well as other markers of Treg function, including IL-10. They suppressed polyclonal CD4+ T cells and antigen-specific CD8+ T cells (recognizing insulin or IGRP), decreasing proliferation and increasing exhaustion and regulatory markers in vitro. In vivo, eTregs reduced diabetes development in co-transfer experiments with pathogenic antigen-specific CD8+ T cells (INS-CD8+ or IGRP-CD8+ cells) into NOD.Scid mice. Finally, when the eTreg were injected into young NOD mice, they reduced insulitis and prevented spontaneous diabetes in the recipient mice. Conclusion: Our results suggest a novel therapeutic strategy to protect NOD mice by targeting antigen-specific cytotoxic CD8+ T cells, using redirected antigen-specific CD4+ Treg cells, to suppress autoimmune diabetes. This may suggest an innovative therapy for protection of people at risk of development of type 1 diabetes.
| Item Type: | Article | 
|---|---|
| Date Type: | Published Online | 
| Status: | Published | 
| Schools: | Schools > Medicine | 
| Additional Information: | License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/ | 
| Publisher: | Frontiers Media | 
| Funders: | MRC | 
| Date of First Compliant Deposit: | 4 October 2024 | 
| Date of Acceptance: | 20 August 2024 | 
| Last Modified: | 15 Oct 2024 14:44 | 
| URI: | https://orca.cardiff.ac.uk/id/eprint/172597 | 
Actions (repository staff only)
![]()  | 
              Edit Item | 

							


    
  
  
        
 Altmetric
 Altmetric